Peter Bui graduated summa cum laude from UCLA with a bachelor’s degree in
microbiology and molecular genetics. Before he came back to a graduate school he
had worked for a biotech company for several years where he was a co-inventor for
3 patents. He then received his Ph.D. in Molecular Toxicology from UCLA.
Currently, he is a postdoctoral fellow in both molecular toxicology and clinical
molecular genetics. His research interests include the possible role of a novel
cytochrome P450 2S1 in colorectal cancer and asthma, and molecular diagnosis of
genetic disorders and cancers.
Curriculum Vitae
Education
1994-1999
B. S., Microbiology and Molecular Genetics
Summa Cum Laude and Departmental Honors
University of California, Los Angeles
2005-2009
Ph.D., Molecular Toxicology
University of California, Los Angeles
2009-present
Molecular Toxicology postdoctoral fellow
Clinical Molecular Genetics Fellow
Dept. of Pathology and Laboratory Medicine,
UCLA
Experience
1999-2004
Research Associate
Biocatalytics, Inc (Codexis, Inc)
Pasadena, CA
2004-2009
Graduate student researcher
Dept. of Pathology and Laboratory Medicine,
UCLA
2006
Teaching Assistant
Department of Molecular, Cell, and Developmental
Biology
University of California, Los Angeles
2009-present
Postdoctoral researcher and clinical molecular
genetics trainee
UCLA
Achievements
2004-2005
University Fellowship Award, UCLA
2005-2008
University of California Toxic Substances Research
and Teaching Fellowship Award
2006
Winner of the best poster at the 19th UCTSR&TP
symposium
San Diego, CA
2006
Winner of the best poster at the Southern California
Society of Toxicology (ScalSOT) meeting
Irvine, CA
2008-2009
University Fellowship Award, UCLA
2009
PUBLICATIONS AND PRESENTATIONS
Bui PH, Hsu EL, Hankinson O (2005). Functional characterization of human and mouse
cytochrome P450 2S1. UC TSR&TP Annual Meeting and Symposia, Riverside, CA
Bui PH, Hsu EL, Hankinson O (2006). Functional characterization of human and mouse
cytochrome P450 2S1 using a bacterial recombinant expression system. 45th annual SOT
conference meeting, the Toxicologist 2006
Bui PH, Hsu EL, Hakinson O (2006). Functional Characterization of Human and Mouse
Extrahepatic Cytochrome P450, CYP2S1. The 19th UCTSR&TP symposium, San Diego,
CA
Bui PH, Hsu EL, Hankinson O (2006). Functional Characterization of Human and Mouse
Extrahepatic Cytochrome P450, CYP2S1. The Southern California SOT annual meeting,
Irvine, CA
Bui PH and Hankinson O (2007). The Role of Cytochrome P450 2S1 in Xenobiotic
Metabolism and Toxicology. The 20th UCTSR&TP symposium, Santa Cruz, CA
Bui PH, Quesada A, Handforth A, Hankinson O (2007). Risk Assessment of Drug-Drug
Interaction for a Novel Therapeutic T-type Ca2+ Channel-Specific Antagonist via P450
Inhibition Study. Southern California SOT annual meeting, Thousand Oaks, CA
Bui PH, Quesada A, Handforth A, Hankinson O (2008). NNC55-0396, a potentially safe
therapeutic T-Type Ca2+ channel-specific antagonist, does not strongly inhibit CYP3A4.
47th annual SOT conference meeting, Seattle, Washington, the toxicologist 2008.
Bui PH and Hankinson O (2009). Characterization of a novel cytochrome P450, CYP2S1
using a protein expressed from a synthetic gene. 48th annual SOT conference meeting,
Baltimore, MD, the toxicologist 2009.
Rozzell JD, Bui PH, and Hua L (2002, 2004, 2005). Synthetic genes for enhanced
expression. U.S patent 6,366,860, 6,818,752, and 20050196774. U.S patent 6,366,860,
6,818,752, and 20050196774.
Bui PH, Quesada A, Handforth A, Hankinson O (2008). The mibefradil derivative
NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4
inhibition than mibefradil. Drug Metabolism Disposition, Jul;36(7):1291-9.
Beedanagari SR, Bebenek I, Bui P, Hankinson O (2009). Resveratrol inhibits dioxininduced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the
Aryl Hydrocarbon Receptor complex and RNA Polymerase II to the regulatory regions of
the corresponding genes. Toxicol Sci. Apr 17.